期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肺癌新靶点药物研究进展 被引量：2

暂未订购
导出
摘要 肺癌的新靶点药物是近几年临床研究和关注的热点 ,主要有表皮生长因子受体 (EGFR)阻断剂、单克隆抗体、诱导分化剂、抗肿瘤血管生成药物、肿瘤耐药逆转剂以及抗肿瘤疫苗等 。
作者 郭其森 于金明
机构地区 山东省肿瘤防治研究院内二科
出处 《国外医学（肿瘤学分册）》 2004年第3期211-214,共4页 Foreign Medical Sciences (Cancer Section)
关键词 肺癌 药物疗法 肿瘤血管生成 药物靶点 细胞信号转导
分类号 R979.1 [医药卫生—药品]
  • 相关文献

参考文献14

  • 1Vzzoli CG, Krug LM, Miller VA, et al. Trastuzumab in the treatment of non-small cell lung cancer. Semin Oncol, 2002,29 ( Suppl4) :59-65.
  • 2Scholl S, Beuzeboc P, Pouillart P. Targeting HER2 in other tumor types. Ann Oncol, 2001 ; 12 (Suppl 1 ) :S81-83.
  • 3Senzer NN, Soulieres D, Siu L, et al: Phase 2 evaluation of OSI774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol,2001,20:5.
  • 4Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER-2 monodonal antibody in women who have HER2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.J Clin Oncol, 1999,17 (9) : 2639-2648.
  • 5Zinner RG, Kim J, Herbst RS. Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results.Lung Cancer, 2002,37 ( 1 ) : 17-27.
  • 6Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase H trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol, 2003, 21(12) : 2237-2246.
  • 7Fujiwara K, Kiura K, Ueoka H, et al. Dramatic effect of ZD1839( Iressa ) in a patient with advanced non-small-cell lung cancer and poor performance status. Lung Cancer, 2003,40( 1 ) : 73-76.
  • 8Volta M, Mattem J, Koomagi R. Angiostatin expression in nonsmall cell lung cancer. Clin Cancer Res, 2000,6(8):3236-3240.
  • 9Joo YE, Seo KS, Kin HS, et al. Expression of tissue inhibitors of metalloproteinases (TIMPs) in gastric cancer. Dig Dis Sci, 2000,45(1):114-121.
  • 10Hutton M, Butler GS, Wattam BA, et al. Analysis of the interaction of TIMP-2 and MMPs: engineering the changes. Ann N Y Acad Sci, 1999, 878(4) :524-527.

同被引文献16

  • 1申文江.表皮生长因子受体与肿瘤治疗[J].癌症进展,2004,2(1):60-63. 被引量：6
  • 2钱军,秦叔逵.针对表皮生长因子受体的靶向治疗研究进展[J].中国药科大学学报,2004,35(3):285-288. 被引量：14
  • 3顾岩,王立红,李国华.非小细胞肺癌的多药耐药[J].中国肿瘤临床与康复,2005,12(2):184-186. 被引量：6
  • 4王立红,顾岩,孙勤暖.非小细胞肺癌肿瘤血管生成研究进展[J].中国肿瘤临床与康复,2005,12(3):280-282. 被引量：1
  • 5管忠震,张力,李龙芸,蒋国梁,刘叙仪,储大同,赵洪云,李玮.吉非替尼治疗局部晚期或转移性非小细胞肺癌在中国的临床研究[J].癌症,2005,24(8):980-984. 被引量：114
  • 6Jemal A, Murray T, Samuels A, et al. Cancer statistics 2003 [ J ]. CA Cancer J Clin, 2003, 53( 1 ): 5-26.
  • 7Giordano A, Rustum YM, Wenner CE. Cell cycle: molecular targets for diagnesis and therapy : tumor suppressor genes and cell cycle progression in cancer [J]. J Cell Biochem, 1998, 70(1): 1-7.
  • 8Judit A, Pablo M, Joan AI, et al. ZD1839, a Specific epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin Signaling in HER2 - overexpressing breast cancer cells [ J ]. Clinical Cancer Research,2003, 9:1274-1283.
  • 9Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa) : an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy[J]. Cancer Res, 2002, 62:5749-5754.
  • 10Moulder SL, Yakes FM, Muthuswamy SK, et al. Epidermal growth factor receptor ( HER1 ) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo [J]. Cancer Res, 2001, 61:8887-8895.

引证文献2

二级引证文献15

国外医学（肿瘤学分册）
2004年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部